Clinical Trials - April 16, 2015
Renal Disease Drug Nails Trial
The NEFIGAN Trial of Pharmalink AB’s Nefecon®, a drug for the treatment of primary IgA nephropathy, was stopped early because the drug fully met its primary efficacy endpoint at a planned interim analysis, according to news from BioSpace.com. The interim analysis, conducted by the Data & Safety Monitoring Board (DSMB), showed that Nefecon treatment, with […]
Clinical Trials - January 14, 2014
Pharmalink completes enrolment of patients into phase IIb clinical study
Pharmalink has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon. Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess the efficacy and safety of two different doses of Nefecon in 90 IgA nephropathy […]
